S&P 500   2,995.68 (+1.00%)
DOW   27,024.80 (+0.89%)
QQQ   193.52 (+1.27%)
AAPL   235.32 (-0.23%)
FB   188.89 (+3.06%)
MSFT   141.58 (+1.45%)
GOOGL   1,242.24 (+2.01%)
AMZN   1,767.38 (+1.78%)
CGC   20.10 (+6.57%)
NVDA   196.37 (+5.28%)
MU   46.46 (+3.54%)
BABA   175.29 (+2.41%)
GE   8.89 (+1.95%)
TSLA   257.89 (+0.36%)
AMD   30.72 (+0.62%)
T   37.90 (+1.15%)
F   9.07 (+2.83%)
ACB   3.76 (+7.12%)
PRI   123.67 (+1.81%)
NFLX   284.25 (-0.45%)
BAC   29.73 (+2.02%)
GILD   65.30 (+1.22%)
DIS   129.76 (+0.05%)
S&P 500   2,995.68 (+1.00%)
DOW   27,024.80 (+0.89%)
QQQ   193.52 (+1.27%)
AAPL   235.32 (-0.23%)
FB   188.89 (+3.06%)
MSFT   141.58 (+1.45%)
GOOGL   1,242.24 (+2.01%)
AMZN   1,767.38 (+1.78%)
CGC   20.10 (+6.57%)
NVDA   196.37 (+5.28%)
MU   46.46 (+3.54%)
BABA   175.29 (+2.41%)
GE   8.89 (+1.95%)
TSLA   257.89 (+0.36%)
AMD   30.72 (+0.62%)
T   37.90 (+1.15%)
F   9.07 (+2.83%)
ACB   3.76 (+7.12%)
PRI   123.67 (+1.81%)
NFLX   284.25 (-0.45%)
BAC   29.73 (+2.02%)
GILD   65.30 (+1.22%)
DIS   129.76 (+0.05%)
Log in

Vycor Medical Stock Price, News & Analysis (OTCMKTS:VYCO)

$0.14
0.00 (0.00 %)
(As of 10/15/2019 04:00 PM ET)
Today's Range
$0.14
Now: $0.14
$0.14
50-Day Range
$0.14
MA: $0.14
$0.14
52-Week Range
$0.03
Now: $0.14
$0.30
VolumeN/A
Average Volume11,408 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Vycor Medical, Inc. designs, develops, and markets neurological medical devices and therapies in the United States and Europe. The company provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage that caused by a stroke. It operates in two segments, Vycor Medical and NovaVision. The Vycor Medical segment provides devices for neurosurgery comprising ViewSite Brain Access System, a retraction and access system for brain and spine surgeries. The NovaVision segment offers non-invasive, computer-based rehabilitation targeted at an un-addressed market of people who have lost their sight as a result of stroke or other brain injury. It offers therapies that restore and compensate for lost vision, including VRT that delivers a series of light stimuli along the border of the patient's visual field loss; Neuro-Eye Therapy (NeET), which targets deep within the blind area by repeated stimulation, allowing patients to detect objects within the blind field; and NeuroEyeCoach, a complementary therapy to VRT and NeET. This segment also provides professional models of VRT and NeuroEyeCoach for physicians; and a clinic-based model comprising NeuroEyeCoach and VIDIT, a diagnostic program that enables therapists to perform high-resolution visual field tests in less than ten minutes. The company primarily serves hospitals and medical professionals. Vycor Medical, Inc. was founded in 2005 and is headquartered in Boca Raton, Florida.

Industry, Sector and Symbol

Industry Medical Devices
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:VYCO
CUSIP92921M203
Phone+1-562-5582000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive VYCO News and Ratings via Email

Sign-up to receive the latest news and ratings for VYCO and its competitors with MarketBeat's FREE daily newsletter.


Vycor Medical (OTCMKTS:VYCO) Frequently Asked Questions

What is Vycor Medical's stock symbol?

Vycor Medical trades on the OTCMKTS under the ticker symbol "VYCO."

How were Vycor Medical's earnings last quarter?

Vycor Medical Inc (OTCMKTS:VYCO) issued its quarterly earnings results on Monday, November, 13th. The medical device company reported ($0.03) EPS for the quarter. The medical device company earned $0.38 million during the quarter. View Vycor Medical's Earnings History.

Has Vycor Medical been receiving favorable news coverage?

Headlines about VYCO stock have been trending extremely negative on Tuesday, according to InfoTrie. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vycor Medical earned a news impact score of -4.2 on InfoTrie's scale. They also assigned headlines about the medical device company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Vycor Medical.

Who are some of Vycor Medical's key competitors?

What other stocks do shareholders of Vycor Medical own?

Who are Vycor Medical's key executives?

Vycor Medical's management team includes the folowing people:
  • Mr. Adrian Christopher Liddell, Chairman, CFO & Director (Age 60)
  • Mr. Peter C. Zachariou, Chief Exec. Officer and Director (Age 57)
  • Mr. David Marc Cantor, Pres & Director (Age 53)

How do I buy shares of Vycor Medical?

Shares of VYCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Vycor Medical's stock price today?

One share of VYCO stock can currently be purchased for approximately $0.14.

What is Vycor Medical's official website?

The official website for Vycor Medical is http://www.vycormedical.com/.

How can I contact Vycor Medical?

Vycor Medical's mailing address is 951 Broken Sound Pkwy NW Ste 320, BOCA RATON, FL 33487-3531, United States. The medical device company can be reached via phone at +1-562-5582000.


MarketBeat Community Rating for Vycor Medical (OTCMKTS VYCO)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  46 (Vote Outperform)
Underperform Votes:  54 (Vote Underperform)
Total Votes:  100
MarketBeat's community ratings are surveys of what our community members think about Vycor Medical and other stocks. Vote "Outperform" if you believe VYCO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VYCO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2019 by MarketBeat.com Staff

Featured Article: Overbought

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel